Table 2A.
Summary of vaccine response for poliovirus types 1, 2, and 3 by study arms
| Vaccine response | Arm A | Arm B | Arm C | Arm D | Fisher’s Exact Test | ||||
|---|---|---|---|---|---|---|---|---|---|
| IPV14+IPV booster | IPV14+fIPV booster | IPV6+fIPV booster | fIPV6/14+fIPV booster | ||||||
| (n=271) | (n=267) | (n=268) | (n=270) | ||||||
| Type 1 | |||||||||
| Vaccine response to primary series | 164/271 | 61% (55–66%) | 141/267 | 53% (47–59%) | 101/268 | 38% (32–44%) | 212/270 | 79% (73–83%) | B v A: p = 0.08 D v A, D v B: p < 0.0001 C v B: p = 0.0005 |
| Priming response | 107/107 | 100% (97–100%) | 124/126 | 98% (94–100%) | 155/167 | 93% (88–96%) | - | - | B v A: p = 0.50 C v B: p = 0.0281 |
| Cumulative vaccine response | 271/271 | 100% (99–100%) | 265/267 | 99% (97–100%) | 256/268 | 96% (92–97%) | - | - | B v A: p = 0.25 C v B: p = 0.0118 |
| Vaccine response to booster | 271/271 | 100% (97–100%) | 264/267 | 99% (97–100%) | 255/268 | 95% (92–97%) | 264/270 | 98% (95–99%) | D v A: p = 0.0150 D v B: p = 0.50 |
| Type 2 | |||||||||
| Vaccine response to primary series | 126/271 | 47% (41–52%) | 123/267 | 46% (40–52%) | 70/268 | 26% (21–32%) | 173/270 | 64% (58–70%) | B v A: p = 0.93 D v A, C v B, D v B: p < 0.0001 |
| Priming response | 143/145 | 99% (95–100%) | 139/144 | 97% (92–99%) | 167/198 | 84% (79–89%) | - | - | B v A: p = 0.28 C v B: p = 0.0003 |
| Cumulative vaccine response | 269/271 | 99% (97–100%) | 262/267 | 98% (96–99%) | 237/268 | 88% (84–92%) | - | - | B v A: p = 0.28 C v B: p < 0.0001 |
| Vaccine response to booster | 267/271 | 99% (96–99%) | 262/267 | 98% (96–99%) | 239/268 | 89% (85–92%) | 260/270 | 96% (93–98%) | D v A: p = 0.11 D v B: p = 0.30 |
| Type 3 | |||||||||
| Vaccine response to primary series | 99/271 | 37% (31–42%) | 97/267 | 36% (31–42%) | 92/268 | 34% (29–40%) | 196/270 | 73% (67–78%) | B v A: p = 1.0 D v A, D v B: p < 0.0001 C v B: p = 0.65 |
| Priming response | 171/172 | 99% (97–100%) | 166/170 | 98% (94–99%) | 170/176 | 97% (93–98%) | - | - | B v A: p = 0.21 C v B: p = 0.75 |
| Cumulative vaccine response | 270/271 | 100% (98–100%) | 263/267 | 99% (96–99%) | 262/268 | 98% (95–99%) | - | - | B v A: p = 0.21 C v B: p= 0.75 |
| Vaccine response to booster | 269/271 | 99% (97–100%) | 261/267 | 98% (95–99%) | 257/268 | 96% (93–98%) | 266/270 | 99% (96–99%) | D v A: p = 0.45 D v B: p = 0.54 |
Data are the percentage of participants with vaccine response expressed as n/N including 95% confidence interval (CI). Vaccine response defined as seroconversion from seronegative (<1:8) to seropositive (≥1:8) after vaccination, or a four-fold rise in antibody titers after vaccination adjusted for maternal antibody decay. Priming defined as absence of vaccine response at 22 weeks with subsequent evidence of response at 23 weeks. Cumulative vaccine response defined as vaccine response at 22 weeks or priming response at 23 weeks. IPV=inactivated poliovirus vaccines. fIPV=fractional inactivated poliovirus vaccine. Fisher’s Exact test was used to test for inequality of proportions between study arms.